All In Biotech

Drug Trial Radar · NCT03859700

Follow-up of the EPITOPE Study to Evaluate Long-term Efficacy and Safety of DBV712 in Young Children

EPITOPE Open-label Extension Study to Evaluate the Long-term Clinical Benefit and Safety of DBV712 in Peanut-Allergic Children

Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

304

Actual

Start

Dec 6, 2018

Primary completion

May 13, 2025

Study completion May 13, 2025

Sponsor

Lead sponsor
DBV TechnologiesIndustry
Sponsor type
Industry
First posted
Mar 1, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 5 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Open-label, follow-up study for subjects who completed the EPITOPE study.

Conditions

  • Peanut Allergy

Interventions

  • DBV712 250 mcgBiological

    DBV712 250 mcg, once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Who Were Treatment Responders at Months 12, 24, 36 and 48Time frame: Months 12, 24, 36 and 48

Locations

26 sites in 1 country. Site status is shown where the registry gives one.

  • Banner University Medical Center Tucson

    Tucson, Arizona

  • Arkansas Children's Hospital

    Little Rock, Arkansas

  • David Geffen School of Medicine at University of California Los Angeles

    Los Angeles, California

  • Rady Children's Hospital San Diego

    San Diego, California

  • University of California San Francisco

    San Francisco, California

  • Stanford University School of Medicine

    Stanford, California

  • Children's Hospital Colorado

    Aurora, Colorado

  • Children's National Health Center

    Washington D.C., District of Columbia

  • Children's Healthcare of Atlanta

    Atlanta, Georgia

  • Ann & Robert H. Lurie Children's Hospital of Chicago

    Chicago, Illinois

  • Comer Children's Hospital

    Chicago, Illinois

  • Riley Hospital for Children

    Indianapolis, Indiana

  • Johns Hopkins Hospital

    Baltimore, Maryland

  • Boston Childrens' Hospital

    Boston, Massachusetts

  • University of Michigan - Allergy Specialty Clinic and Food Allergy Clinic

    Ann Arbor, Michigan

  • Mount Sinai Medical Center

    New York, New York

  • University of Rochester

    Rochester, New York

  • The University of North Carolina - Chapell Hill

    Chapel Hill, North Carolina

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • UPMC Children's Hospital of Pittsburgh

    Pittsburgh, Pennsylvania

  • Le Bonheur Children's Hospital

    Memphis, Tennessee

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • Dell Children's Medical Center of Central Texas

    Austin, Texas

  • Children's Medical Center Dallas

    Dallas, Texas

  • Baylor College of Medicine

    Houston, Texas

  • Seattle Allergy & Asthma Research Institute

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.